1. Academic Validation
  2. New Multitarget Inhibitor Potentiates Antimicrobial Activity of Aztreonam against Metallo-β-lactamase-Producing Pseudomonas aeruginosa Including IMP-Types

New Multitarget Inhibitor Potentiates Antimicrobial Activity of Aztreonam against Metallo-β-lactamase-Producing Pseudomonas aeruginosa Including IMP-Types

  • J Med Chem. 2026 Mar 12;69(5):5560-5574. doi: 10.1021/acs.jmedchem.5c02664.
Jihyeok Kang 1 Dahee Lee 1 Mi Kyoung Kim 1 Joong Hoon Ahn 1 Tae-Won Kim 2 Jisun Park 3 Hwi Won Seo 3 Tae Kun Ahn 4 Eun Kyoung Chung 5 Ki-Ho Park 6 Youhoon Chong 1
Affiliations

Affiliations

  • 1 Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Neungdong-ro 120, Gwangjin-gu, Seoul 05029, Korea.
  • 2 College of Veterinary Medicine (BK21 FOUR Program), Chungnam National University, 99 Daehak-ro, Daejeon 34131, Republic of Korea.
  • 3 Infectious Disease Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Korea.
  • 4 Department of Regulatory Science, Institutes of Regulatory Innovation through Science and Integrated Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea.
  • 5 Departments of Pharmacy and Regulatory Science, Institutes of Regulatory Innovation through Science (IRIS) and Integrated Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea.
  • 6 Department of Infectious Disease, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea.
Abstract

Combination of aztreonam (ATM) and avibactam (AVI) was proven to be synergistic against Metallo-β-lactamase (MBL)-producing Enterobacteriaceae. However, in the case of Pseudomonas aeruginosa (PA), ATM-potentiation by AVI can hardly be achieved because PA has complex resistance mechanisms. In this study, we identified 3,7-bis-O-substituted difluoroquercetin derivatives 9 and 12 as new ATM-potentiating agents against the MBL-producing PAs through the simultaneous inhibition of NDM-1, OXA-10, and efflux pumps. Even though the inhibitory activity of 9 and 12 against the ATM-hydrolyzing β-lactamases (NDM-1 and OXA-10) as well as the efflux pumps is moderate, the simultaneous inhibition of multiple resistance mechanisms seems to result in remarkable potentiation of ATM against this formidable pathogen. Particularly, the IMP-producing CRPAs resistant to the most promising MBL-inhibitors were sensitized to ATM upon combination with compounds 9 and 12. Compound 9 demonstrated potent in vivo rescue of ATM activity in a murine thigh Infection model.

Figures
Products